A groundbreaking daily pill for endometriosis treatment, relugolix-estradiol-norethisterone (Ryeqo), has been approved for use on the NHS in England. This marks a significant advancement in managing the condition, offering a non-invasive alternative to existing treatments like injections and surgery. The approval aims to improve access to effective care for thousands of women suffering from the debilitating symptoms of endometriosis.
Endometriosis affects approximately 1.5 million women in the UK, causing chronic pelvic pain, heavy menstrual bleeding, fatigue, and fertility issues. Current treatments often include hormone injections or surgery, which can have severe side effects and require frequent hospital visits. Ryeqo works by blocking specific hormones that fuel endometriosis while incorporating hormone replacement therapy to prevent side effects such as bone loss.
One of the key advantages of this new treatment is its convenience. Unlike injections, which require administration in a clinical setting, Ryeqo is a once-daily pill that can be taken at home. This provides patients with more control over their treatment and reduces pressure on NHS resources. It is estimated that around 1,000 women who have not responded to other treatments will benefit from this medication annually.
Experts and advocacy groups have welcomed the approval, calling it a long-overdue breakthrough for endometriosis patients. Many women struggle for years before receiving a proper diagnosis and effective treatment, leading to a diminished quality of life. By offering an easily accessible and less invasive option, the NHS hopes to close the treatment gap and provide relief to those affected.
This approval represents a step forward in improving healthcare for women with endometriosis, but campaigners continue to push for increased awareness, research, and better diagnostic processes. While Ryeqo offers a promising solution, experts stress that more work is needed to ensure early diagnosis and comprehensive care for all women suffering from this often-overlooked condition.
